Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | PROCURE: Genomic signatures and adjuvant chemotherapy for breast cancer in Europe

Giuseppe Curigliano • 9 Dec 2021
SABCS 2021
Breast Cancer
PROCURE RxPONDER

Giuseppe Curigliano, MD, PhD, University of Milan and European Institute of Oncology, Milan, Italy, discusses the PROCURE project, a survey across European investigators about use of genomic signatures to make decisions about adjuvant chemotherapy use in early breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Disclosures

Consultation fees from Pfizer, Roche, Astra Zeneca, BMS, Daichii Sankyo, Seagen, Gilead, Novartis, Lilly; Ellipsis, Merck

More from Giuseppe Curigliano

6:54
Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer
Giuseppe Curigliano • 9 Dec 2021
2:52
Future research directions for breast cancer
Giuseppe Curigliano • 9 Dec 2021
1:51
Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer
Giuseppe Curigliano • 25 Mar 2021
3:10
Highlights from the St. Gallen Consensus Panel
Giuseppe Curigliano • 24 Mar 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals